Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. - Wikidata - awgldk - TriplyDB

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.

http://www.wikidata.org/entity/Q35012335

about

Roles of HTLV-1 basic Zip Factor (HBZ) in Viral Chronicity and Leukemic Transformation. Potential New Therapeutic Approaches to Prevent and Treat HTLV-1-Related Diseases The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia Common gamma chain cytokines in combinatorial immune strategies against cancer Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.Mature T-cell leukemias: Molecular and Clinical Aspects.Daclizumab for the treatment of multiple sclerosis.Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?Adult T-cell leukemia/lymphoma in South and Central America and the Caribbean: systematic search and review.Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens.The effect of the JAK2 inhibitor TG101209 against T cell acute lymphoblastic leukemia (T-ALL) is mediated by inhibition of JAK-STAT signaling and activation of the crosstalk between apoptosis and autophagy signaling.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies.Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose.Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma.

P2860

Q26774352-86BCA344-7AEB-4660-BEF9-F93E7A6219EE Q28088784-F303C558-AC2B-41F7-BF7A-8434484A1DE3 Q33434322-A4644E02-8B8E-4A72-98C9-1471F38F0554 Q35691210-1BEDFBA3-CBCB-4ACA-A2D1-2DE62469D264 Q36155080-B9237B6D-4A37-4D2C-9BC1-B9FCCEAE8147 Q36455872-B717EB4F-A45C-4684-A8A5-BA340D002B77 Q38598544-14634EE5-D719-4B93-8C34-79356E6E01C0 Q38598546-197BDDE3-2E45-4FB2-B47B-3D6A860E5818 Q38604207-1B04ECE9-6D3D-4513-82C1-E7530D62B7A1 Q38952071-2A5FDF2C-BD0B-4A25-A8B6-D81EA3AEF878 Q39126807-5C2241F4-B3EC-4017-AF96-AF71F94A4C86 Q44779448-E702EFFA-C2F3-4A1D-A457-A9305C6D977C Q47147269-8014066B-48D2-4509-98C4-96D0C725CF2E Q49539698-81E2120D-EA93-41D5-A127-531D60A0A903 Q50145911-F5107E61-F1A8-47AC-A68B-8D6C9797151E Q52317280-1BDBD80E-1E19-41AE-B0CE-4AD4FCD49B92 Q52846906-EFAE4D7C-44C1-4D6F-A2E4-28F4BCE8A520 Q54941716-6F71B2D6-FAA8-4CAC-9D73-7A172916095F

P2860

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.

http://www.wikidata.org/entity/Q35012335

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Safety, efficacy, and pharmaco ...... dult T-cell leukemia/lymphoma.

@ast

Safety, efficacy, and pharmaco ...... dult T-cell leukemia/lymphoma.

@en

type

label

Safety, efficacy, and pharmaco ...... dult T-cell leukemia/lymphoma.

@ast

Safety, efficacy, and pharmaco ...... dult T-cell leukemia/lymphoma.

@en

prefLabel

Safety, efficacy, and pharmaco ...... dult T-cell leukemia/lymphoma.

@ast

Safety, efficacy, and pharmaco ...... dult T-cell leukemia/lymphoma.

@en

P1433

Q35012335-BA2B0D64-DD31-44E2-BF1B-5ECB827AC812

P1476

Q35012335-88379C9F-38D7-465A-9813-FBE84E5A4CAF

P2093

Q35012335-0231C982-9372-475E-9DA9-8C876F21A523

Q35012335-30CA0DC1-782D-4C31-8673-5356B9B5F081

Q35012335-3A73C0CA-7F99-4382-8CDE-5C154A6FC3D1

Q35012335-79E79DFB-45D0-4BD0-B884-BAB676682D9D

Q35012335-8D31291B-295E-4F4A-AB4D-17257B516244

Q35012335-8F51ED7B-58EA-4923-B916-62043BD2644A

Q35012335-90337E33-2AC3-4D4F-BB75-9A335532B4AE

Q35012335-9B059BE9-18A6-4F8D-9C90-5E241D0FBBD6

Q35012335-A373FE6E-CCF3-4C7B-9BC6-9C433553BD60

Q35012335-B4A65A5A-A6D1-4555-B429-1E5ED05CA4EF

P2860

Q35012335-08AC37D0-F054-4980-98A4-67A7A5620D96

Q35012335-08DB2EDA-0669-42F9-82DC-FA646162CA21

Q35012335-0B206CCE-25D4-4523-BBE1-5EEB84E57323

Q35012335-0CE3DD6E-5C46-4935-ADCA-10D4B00A18BE

Q35012335-12BCDA8C-39B4-4372-B099-9FDEEFF6E28E

Q35012335-1869EAC9-4F4F-43B3-8DDA-1D68B6051F41

Q35012335-1D9738D9-1E28-420E-A9AB-1863EB5A1CE8

Q35012335-1FC8AFF2-E173-4221-96D7-3B3E3FEC3811

Q35012335-34926AB7-3699-4328-9414-50DD5D72C98E

Q35012335-38E54C50-997E-4FA3-8CA8-5500B059A184

P304

Q35012335-B7E50336-FCF2-4EF7-B895-953564999152

P31

Q35012335-ED95BFBC-E4B4-4602-91A6-39FED2503CD2

P356

Q35012335-4D3AB602-A9F8-4A48-BCC8-2BD1971BF3EA

P433

Q35012335-41E58BE5-7FB5-4762-BB94-D092C6E153A3

P478

Q35012335-EECCDF07-B34B-4C98-877A-A94090B65427

P577

Q35012335-2FF8985B-308C-4F6D-8F0F-DE0693D927F8

P5875

Q35012335-030DA64F-0BC2-4280-9FF9-FE6ABC020865

P698

Q35012335-135546CD-11D3-4D5F-9101-93EAC52319FC

P932

Q35012335-4DD9231B-279E-439B-8F45-47775B1033FE

P356

J.CLIM.2014.09.012

P1433

Clinical Immunology

P1476

Safety, efficacy, and pharmaco ...... dult T-cell leukemia/lymphoma.

@en

P2093

Carolyn K Goldman

http://www.w3.org/2001/XMLSchema#string

Cody J Peer

http://www.w3.org/2001/XMLSchema#string

Donn M Stewart

http://www.w3.org/2001/XMLSchema#string

Elaine S Jaffe

http://www.w3.org/2001/XMLSchema#string

Gilian H Wharfe

http://www.w3.org/2001/XMLSchema#string

Joanna H Shih

http://www.w3.org/2001/XMLSchema#string

John C Morris

http://www.w3.org/2001/XMLSchema#string

John E Janik

http://www.w3.org/2001/XMLSchema#string

Jonathan L Berkowitz

http://www.w3.org/2001/XMLSchema#string

Maria Turner

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin 2 receptor antagonists for kidney transplant recipients

A humanized antibody that binds to the interleukin 2 receptor

Daclizumab therapy for multiple sclerosis

''R"--project for statistical computing

VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients.

Adult T-cell leukemia: clinical and hematologic features of 16 cases.

Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia

P304

176-187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLIM.2014.09.012

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

155

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266149236

http://www.w3.org/2001/XMLSchema#string

P698

25267440

http://www.w3.org/2001/XMLSchema#string

P932

4306230

http://www.w3.org/2001/XMLSchema#string